^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12D

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) (NCT06599502)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/18/2024
    Primary completion :
    01/20/2028
    Completion :
    01/20/2028
    KRAS
    |
    KRAS mutation • KRAS G12D
    |
    Erbitux (cetuximab)
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    A Study of ASP3082 in Adults With Advanced Solid Tumors (3082-CL-0101) (NCT05382559)
    Phase 1
    Astellas Pharma Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/08/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • setidegrasib (ASP3082)
    Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors (KEYNOTE-E28) (NCT04429542)
    Phase 1
    Bicara Therapeutics
    Recruiting
    Last update posted :
    01/27/2025
    Initiation :
    06/01/2020
    Primary completion :
    12/31/2026
    Completion :
    06/01/2027
    PD-L1
    |
    KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation (TRIAD1) (NCT06667544)
    Phase 1/2
    Ranok Therapeutics (Hangzhou) Co., Ltd.
    Not yet recruiting
    Last update posted :
    10/31/2024
    Initiation :
    12/01/2024
    Primary completion :
    12/01/2026
    Completion :
    07/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12D
    A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (NCT06385925)
    Phase 1/2
    Tyligand Bioscience (Shanghai) Limited
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    04/29/2024
    Primary completion :
    10/30/2026
    Completion :
    04/30/2027
    KRAS
    |
    KRAS mutation • KRAS G12D
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (19-C-0017) (NCT03745326)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/16/2019
    Primary completion :
    12/01/2027
    Completion :
    12/01/2028
    EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous
    A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer (NCT04586270)
    Phase 1
    Taiho Oncology, Inc.
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/15/2020
    Primary completion :
    08/01/2024
    Completion :
    07/01/2027
    HER-2 • KRAS • PTEN • NF1
    |
    KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative
    |
    TAS0612
    A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02) (NCT05846516)
    Phase 1
    Amal Therapeutics
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    03/13/2023
    Primary completion :
    12/01/2026
    Completion :
    03/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12V • KRAS G12
    |
    ezabenlimab (BI 754091) • ATP150 • ATP152 • Kisima (ATP128) • VSV-GP154
    A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers (NCT05786924)
    Phase 1
    Black Diamond Therapeutics, Inc.
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    04/18/2023
    Primary completion :
    06/01/2026
    Completion :
    12/01/2026
    KRAS • BRAF • NRAS
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12 • NRAS G12D
    |
    S241656
    DC Vaccine in Pancreatic Cancer (NCT03592888)
    Phase 1
    University of Pennsylvania
    Completed
    Last update posted :
    05/07/2024
    Initiation :
    11/20/2018
    Primary completion :
    02/12/2024
    Completion :
    02/12/2024
    KRAS • HLA-A
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) (NCT05726864)
    Phase 1/2
    Elicio Therapeutics
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    04/14/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    KRAS • NRAS
    |
    KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V
    |
    ELI-002 7P